Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence

Blog Article

Abstract Background The impact of direct-acting antivirals (DAAs) remains a debate, whether they accelerate the recurrence rate of hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) after curative therapy.We evaluated the impact of direct-acting antiviral therapy on Grooming the rate of recurrence of HCV-related hepatocellular carcinoma following intervention in Egyptian patients.Results The results of the study represented an HCC recurrence rate of 38% in patients who received direct-acting antiviral therapy after HCC intervention versus 62% in those who did not receive antiviral therapy.In group I, according to the Barcelona Clinic of Liver Cancer (BCLC) staging, a higher recurrence rate was observed (57.

9%) among patients who were classified as BCLC stage B.Conclusions HCC patients who did not receive direct-acting antiviral therapy after HCC intervention had a greater risk of HCC recurrence.DAAs did not increase the risk of HCC RANGEMASTER Professional Deluxe PDL110DFFGB/C 110 cm Dual Fuel Range Cooker recurrence following HCC treatment; however, it did not abolish it.Close monitoring of patients after antiviral therapy is recommended.